الإحصائيات الأساسية
| LEI | 5493004MZJQIV2K8ZT61 |
| CIK | 1640455 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Jounce Therapeutics Inc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| February 14, 2024 |
JNCE / Jounce Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-jnce123123a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* JOUNCE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 9, 2024 |
JNCE / Jounce Therapeutics Inc / Opaleye Management Inc. Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 481116101 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Jounce Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 481116101 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-37998 Commission File Number JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in |
|
| May 5, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 4 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the securities exchange act of 1934 (amendment no. |
|
| May 4, 2023 |
Lease Termination Agreement, by and between the Company and the Landlord, dated May 2, 2023. Exhibit 10.1 AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES This Agreement for Termination of Lease and Voluntary Surrender of Premises (this “Agreement”) is made and entered into as of May 2, 2023 (the “Effective Date”), by and between ARE-770/784/790 MEMORIAL DRIVE, LLC, a Delaware limited liability company (“Landlord”), and JOUNCE THERAPEUTICS, INC., a Delaware corporati |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
Amended and Restated Bylaws of Jounce Therapeutics, Inc. Exhibit 3.2 BYLAWS OF JOUNCE THERAPEUTICS, INC. (a Delaware corporation) (Adopted as of March 3, 2023) Article I CORPORATE OFFICES Section 1.1Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) JOUNCE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Co-Offeror |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
EX-99.(d)(5) Exhibit (d)(5) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of May 3, 2023 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), Computershare Inc., a Delaware c |
|
| May 4, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Jounce Therapeutics, Inc. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Subject Company) Jounce Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Secur |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
As filed with the Securities and Exchange Commission on May 4, 2023 As filed with the Securities and Exchange Commission on May 4, 2023 Registration No. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 4, 2023 |
Press release issued by Company on May 3, 2023. Exhibit 99.1 Jounce Therapeutics Announces Closing of Tender Offer Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights CAMBRIDGE, Mass., May 3, 2023-(GLOBE NEWSWIRE) – Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announ |
|
| May 4, 2023 |
Amended and Restated Certificate of Incorporation of Jounce Therapeutics, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF JOUNCE THERAPEUTICS, INC. I. The name of this corporation is Jounce Therapeutics, Inc. (the “Corporation”). II. The registered office of the corporation in the State of Delaware shall be Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801, and the name of the registered agent o |
|
| April 28, 2023 |
EX-99.(a)(1)(G) Exhibit (a)(1)(G) Supplement No. 2 to Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. At $1.85 per Share in Cash, Plus One Non-Transferable Contractual Contingent Value Right for Each Share (“CVR”), Which Represents the Right to Receive One or More Payments in Cash, Contingent upon Receipt of Proceeds from Disposition of CVR Products during the |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001 |
|
| April 28, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) JOUNCE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of C |
|
| April 25, 2023 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Supplement to Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. At $1.85 per Share in Cash, Plus One Non-Transferable Contractual Contingent Value Right for Each Share (“CVR”), Which Represents the Right to Receive One or More Payments in Cash, Contingent upon Receipt of Proceeds from Disposition of CVR Products during the Dispo |
|
| April 25, 2023 |
EX-99.(a)(1)(F) Exhibit (a)(1)(F) Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. At $1.85 per Share in Cash, Plus One Non-Transferable Contractual Contingent Value Right for Each Share (“CVR”), Which Represents the Right to Receive One or More Payments in Cash, Contingent upon Receipt of Proceeds from Disposition of CVR Products during th |
|
| April 25, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) JOUNCE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of C |
|
| April 24, 2023 |
April 24, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers & Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attention: Christina Chalk and Blake Grady Re: Jounce Therapeutics, Inc. Schedule 14D-9 filed April 6, 2023 File No. 005-89831 Ladies and Gentlemen: On behalf of Jounce Therapeutics, Inc. (the “Company”), we are writing in respo |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Subject Company) Jounce Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Secur |
|
| April 12, 2023 |
JNCE / Jounce Therapeutics Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 481116101 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Authorized to Receive N |
|
| April 7, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 3 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the securities exchange act of 1934 (amendment no. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Subject Company) Jounce Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUS |
|
| April 5, 2023 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. a Delaware corporation at $1.85 PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CONTINGENT UPON RECEIPT OF PROCEEDS FROM THE DISPOSITION OF CVR PRODUCTS DUR |
|
| April 5, 2023 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of JOUNCE THERAPEUTICS, INC. a Delaware corporation at $1.85 PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT FOR EACH SHARE Pursuant to the Offer to Purchase Dated April 5, 2023 by CONCENTRA MERGER SUB, INC. a wholly owned subsidiary of CONCENTRA BIOSCIENCES, LLC THE OFFER AND W |
|
| April 5, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Jounce Therapeutics, Inc. |
|
| April 5, 2023 |
EX-99.(d)(4) Exhibit (d)(4) TANG CAPITAL PARTNERS, LP 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO, CA 92121 (858) 200-3830 FAX (858) 200-3837 Equity Commitment and Guarantee Letter March 26, 2023 Michael Hearne, Chief Financial Officer Concentra Biosciences, LLC 4747 Executive Drive, Suite 210 San Diego, CA 92121 Dear Mr. Hearne: Reference is made to the Agreement and Plan of Merger, dated as of th |
|
| April 5, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 JOUNCE THERAPEUTICS, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB, INC. (Name of Filing Persons (Offeror)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) Common Stock, Pa |
|
| April 5, 2023 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. a Delaware corporation at $1.85 PER SHARE IN CASH, PLUS ONE NON-TRANSFERABLE CONTRACTUAL CONTINGENT VALUE RIGHT (“CVR”) FOR EACH SHARE, WHICH REPRESENTS THE RIGHT TO RECEIVE ONE OR MORE PAYMENTS IN CASH, CONTINGENT UPON RECEIPT OF PROCEEDS FROM THE DISPOSITION OF CVR PRODUCTS DUR |
|
| April 5, 2023 |
EX-99.(d)(2) Exhibit (d)(2) MUTUAL CONFIDENTIALITY AGREEMENT THIS MUTUAL CONFIDENTIALITY AGREEMENT (the “Agreement”) is made as of March 15, 2023 (the “Effective Date”) by and between Jounce Therapeutics, Inc., a Delaware corporation with an office at 780 Memorial Drive, Cambridge, MA 02139 (“Jounce”) and Concentra Biosciences, LLC, a Delaware limited liability company and its controlling sharehol |
|
| April 5, 2023 |
EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of JOUNCE THERAPEUTICS, INC. At $1.85 per Share in Cash, Plus One Non-Transferable Contractual Contingent Value Right for Each Share (“CVR”), Which Represents the Right to Receive One or More Payments in Cash, Contingent upon Receipt of Proceeds from Disposition of CVR Products during the D |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 JOUNCE THERAPEUTICS, INC. (Name of Subject Company) JOUNCE THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Num |
|
| April 3, 2023 |
Press release, dated April 3, 2023, issued by the Company. Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc CAMBRIDGE, Mass., April 3, 2023 – Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Red |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 2 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the securities exchange act of 1934 (amendment no. |
|
| March 27, 2023 |
Press release, dated March 27, 2023, issued by the Company. Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights CAMBRIDGE, Mass., March 27, 2023 – Jounce Therapeu |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT PURSUANT TO SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 JOUNCE THERAPEUTICS, INC. (Name of Subject Company) JOUNCE THERAPEUTICS, INC. (Name of Person(s) Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Num |
|
| March 27, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB, INC. and JOUNCE THERAPEUTICS, INC. Dated as of March 26, 2023 TABLE OF CONTENTS Page Article I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Offer Documents 3 Section 1.3 Company Actions 4 Article II THE MERGER 5 Section 2.1 The Merger 5 Section 2.2 Closing 5 Section 2.3 Effective Time 5 Section 2.4 |
|
| March 27, 2023 |
Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights CAMBRIDGE, Mass., March 27, 2023 – Jounce Therapeu |
|
| March 17, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D/A Under the securities exchange act of 1934 (amendment no. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 15, 2023 |
Press Release of the Company dated March 14, 2023 Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences CAMBRIDGE, Mass., March. 14, 2023 – The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 15, 2023 |
Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences CAMBRIDGE, Mass., March. 14, 2023 – The Board of Directors (the “Board”) of Jounce Therapeutics, Inc. |
|
| March 14, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| March 13, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Jounce Therapeutics, Inc. |
|
| March 13, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2023 |
Exhibit 10.3 Amendment to Restricted Stock Unit Award Agreement for Company Employees under the 2017 Plan This Amendment to the Restricted Stock Unit Award Agreement for Company Employees under Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan (this “Amendment”) is made as of January 13, 2023 by Jounce Therapeutics, Inc. (the “Company”). Background A. The Grantee has been awarded Rest |
|
| March 10, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Percentage Ownership Jounce Mass Securities, Inc. Massachusetts 100% |
|
| March 10, 2023 |
Exhibit 10.23 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this "First Amendment") is made as of March 21, 2017, by and between ARE-770/784/790 MEMORIAL DRIVE, LLC, a Delaware limited liability company ("Landlord"), and JOUNCE THERAPEUTICS, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of November 1, 201 |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERAP |
|
| March 10, 2023 |
Form of Non-Qualified Stock Option Agreement Inducement Grant for Employees, as amended Exhibit 10.4 NON-QUALIFIED STOCK OPTION AGREEMENT INDUCEMENT GRANT FOR COMPANY EMPLOYEES FOR JOUNCE THERAPEUTICS, INC. Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Vesting Commencement Date: Grant Date: Expiration Date: Jounce Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option” or the “Award”) to purchase on or pr |
|
| March 6, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Jounce Therapeutics, Inc. and further agree to the filing of this agreement as an exhibit th |
|
| March 6, 2023 |
JNCE / Jounce Therapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 23, 2023 |
Consulting Agreement, by and between the Company and Hugh Cole, dated as of February 22, 2023 Exhibit 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Hugh Cole, an individual residing at [***] (hereinafter “Consultant”) and Jounce Therape |
|
| February 23, 2023 |
Exhibit 99.6 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of February , 2023, is entered into by and among Redx Pharma plc, a publicly listed company organized in the United Kingdom (“Target”), Jounce Therapeutics, Inc., a Delaware corporation (“Parent”) and one or more persons set forth on Schedule A hereto (each, a “Stockholder” an |
|
| February 23, 2023 |
Exhibit 2.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT A U.S. PROXY STATEMENT AND INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISION IN RELATION TO THE EXISTING JOUNCE SHARES OR NEW SHARES E |
|
| February 23, 2023 |
Exhibit 10.6 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Richard Murray, Ph.D., an individual residing at [***] (hereinafter “Consultant”) and Jo |
|
| February 23, 2023 |
exhibit22cooperationagre Exhibit 2.2 (1) JOUNCE THERAPEUTICS, INC. (2) REDX PHARMA PLC CO-OPERATION AGREEMENT COOLEY (UK) LLP, 22 BISHOPSGATE, LONDON EC2N 4BQ, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM CONTENTS Clause Page 1. Definitions and interpretation .................................................................................................... 1 2. Publication o |
|
| February 23, 2023 |
Form of Voting and Support Agreement Exhibit 99.6 Execution Version VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of February , 2023, is entered into by and among Redx Pharma plc, a publicly listed company organized in the United Kingdom (“Target”), Jounce Therapeutics, Inc., a Delaware corporation (“Parent”) and one or more persons set forth on Schedule A hereto (each, a “Stockholder” an |
|
| February 23, 2023 |
exhibit22cooperationagre Exhibit 2.2 (1) JOUNCE THERAPEUTICS, INC. (2) REDX PHARMA PLC CO-OPERATION AGREEMENT COOLEY (UK) LLP, 22 BISHOPSGATE, LONDON EC2N 4BQ, UK T: +44 (0) 20 7583 4055 F: +44 (0) 20 7785 9355 WWW.COOLEY.COM CONTENTS Clause Page 1. Definitions and interpretation .................................................................................................... 1 2. Publication o |
|
| February 23, 2023 |
Consulting Agreement, by and between the Company and Hugh Cole, dated as of February 22, 2023 Exhibit 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Hugh Cole, an individual residing at [***] (hereinafter “Consultant”) and Jounce Therape |
|
| February 23, 2023 |
Exhibit 10.1 Amendment No. 1 to Employment Agreement This Amendment No. 1 to the Employment Agreement (this “Amendment No. 1), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Hugh Cole (the “Executive”). Background A. Jounce and the Executive are parties to that certain Empl |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 23, 2023 |
Press Release of the Company, dated February 22, 2023 Exhibit 99.8 Jounce Therapeutics Announces Restructuring CAMBRIDGE, Mass., February 22, 2023 – Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce bel |
|
| February 23, 2023 |
Exhibit 99.7 Redx and Jounce Announce Recommended Business Combination Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jo |
|
| February 23, 2023 |
Form of Deed of Irrevocable Undertaking given by Redx Directors Exhibit 99.5 Execution version DIRECTOR’S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive Cambridge Massachusetts, 2139 United States From: [Director] [Address] 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma PLC ("Target") – Deed of Irrevocable Undertaking 1.I understand that the Offeror (on behalf of it and its affiliates, |
|
| February 23, 2023 |
Exhibit 10.2 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Kim C. Drapkin (the “Executive”). Background A. Jounce an |
|
| February 23, 2023 |
Exhibit 10.4 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Elizabeth Trehu, M.D. (the “Executive”). Background A. Jo |
|
| February 23, 2023 |
Exhibit 2.3 AGREEMENT AND PLAN OF MERGER by and among JOUNCE THERAPEUTICS, INC., EVERGREEN MERGER SUB 1, LLC, and RM SPECIAL HOLDINGS 3, LLC Dated as of February 23, 2023 TABLE OF CONTENTS Page ARTICLE I The Mergers 5 SECTION 1.01. The Mergers 5 SECTION 1.02. Closing 5 SECTION 1.03. Effective Time 6 SECTION 1.04. Effects 6 SECTION 1.05. Organizational Documents. 6 SECTION 1.06. Officers 7 ARTICLE |
|
| February 23, 2023 |
Exhibit 99.2 EXECUTION VERSION SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareholder [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf |
|
| February 23, 2023 |
SHAREHOLDER'S IRREVOCABLE UNDERTAKING Exhibit 99.3 Execution Version SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareolder [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf |
|
| February 23, 2023 |
DIRECTOR’S IRREVOCABLE UNDERTAKING Exhibit 99.5 Execution version DIRECTOR’S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive Cambridge Massachusetts, 2139 United States From: [Director] [Address] 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma PLC ("Target") – Deed of Irrevocable Undertaking 1.I understand that the Offeror (on behalf of it and its affiliates, |
|
| February 23, 2023 |
Jounce Therapeutics Announces Restructuring Exhibit 99.8 Jounce Therapeutics Announces Restructuring CAMBRIDGE, Mass., February 22, 2023 – Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent. The decision to reduce its workforce was made as Jounce bel |
|
| February 23, 2023 |
SHAREHOLDER'S IRREVOCABLE UNDERTAKING Exhibit 99.1 EXECUTION VERSION SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareholder 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf of it |
|
| February 23, 2023 |
Exhibit 10.3 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Richard Murray, Ph.D. (the “Executive”). Background A. Jo |
|
| February 23, 2023 |
Exhibit 10.3 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Richard Murray, Ph.D. (the “Executive”). Background A. Jo |
|
| February 23, 2023 |
Exhibit 10.2 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Kim C. Drapkin (the “Executive”). Background A. Jounce an |
|
| February 23, 2023 |
Exhibit 10.7 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Elizabeth Trehu, M.D., an individual with an address of [***] (hereinafter “Consultant”) |
|
| February 23, 2023 |
Exhibit 99.1 EXECUTION VERSION SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareholder 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf of it |
|
| February 23, 2023 |
Exhibit 99.4 Execution Version SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: [***] (“Supporting Shareholder”) [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror |
|
| February 23, 2023 |
Exhibit 2.3 AGREEMENT AND PLAN OF MERGER by and among JOUNCE THERAPEUTICS, INC., EVERGREEN MERGER SUB 1, LLC, and RM SPECIAL HOLDINGS 3, LLC Dated as of February 23, 2023 TABLE OF CONTENTS Page ARTICLE I The Mergers 5 SECTION 1.01. The Mergers 5 SECTION 1.02. Closing 5 SECTION 1.03. Effective Time 6 SECTION 1.04. Effects 6 SECTION 1.05. Organizational Documents. 6 SECTION 1.06. Officers 7 ARTICLE |
|
| February 23, 2023 |
Exhibit 10.4 Amendment No. 1 to Amended and Restated Employment Agreement This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Elizabeth Trehu, M.D. (the “Executive”). Background A. Jo |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 23, 2023 |
Exhibit 10.6 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Richard Murray, Ph.D., an individual residing at [***] (hereinafter “Consultant”) and Jo |
|
| February 23, 2023 |
Exhibit 10.7 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Elizabeth Trehu, M.D., an individual with an address of [***] (hereinafter “Consultant”) |
|
| February 23, 2023 |
Exhibit 99.3 Execution Version SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareolder [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf |
|
| February 23, 2023 |
SHAREHOLDER'S IRREVOCABLE UNDERTAKING Exhibit 99.4 Execution Version SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: [***] (“Supporting Shareholder”) [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror |
|
| February 23, 2023 |
Joint Press Release of the Company and Redx, dated February 23, 2023 Exhibit 99.7 Redx and Jounce Announce Recommended Business Combination Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jo |
|
| February 23, 2023 |
SHAREHOLDER'S IRREVOCABLE UNDERTAKING Exhibit 99.2 EXECUTION VERSION SHAREHOLDER'S IRREVOCABLE UNDERTAKING To: Jounce Therapeutics, Inc. (the "Offeror") 780 Memorial Drive, Cambridge Massachusetts, 02139 United States From: Supporting Shareholder [***] 23 February 2023 To whom it may concern, Proposed acquisition of and merger with Redx Pharma Plc ("Target") – Deed of Irrevocable Undertaking 1.We understand that the Offeror (on behalf |
|
| February 23, 2023 |
Exhibit 2.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT A U.S. PROXY STATEMENT AND INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISION IN RELATION TO THE EXISTING JOUNCE SHARES OR NEW SHARES E |
|
| February 23, 2023 |
Exhibit 10.1 Amendment No. 1 to Employment Agreement This Amendment No. 1 to the Employment Agreement (this “Amendment No. 1), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Hugh Cole (the “Executive”). Background A. Jounce and the Executive are parties to that certain Empl |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / BANK OF AMERICA CORP /DE/ Passive Investment SC 13G 1 doc1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Jounce Therapeutics Inc (Name of Issuer) Common Stock (Title of Class of Securities) 4811161011 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2023 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION EX-99 2 boa-poa2.htm BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Kelvin Kwok, Tolu Tade, Andres Ortiz Custodio, Frank Lui, James Todd, Zainab Tarteel, Hannah Chae and Monica Yako as an attorney-in-fact for the Corporation acting for the Corporation and in the Corpora |
|
| February 14, 2023 |
EX-99 2 ss1758581ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of Jounce Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the S |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss1758581sc13g.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / Third Rock Ventures II, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d257659dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3 )* Jounce Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment |
|
| February 14, 2023 |
JNCE / Jounce Therapeutics Inc / RTW INVESTMENTS, LP - JOUNCE THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p23-0489sc13ga.htm JOUNCE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this stateme |
|
| January 23, 2023 |
SC 13G/A 1 jncea112323.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jounce Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 481116101 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the app |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 5, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 27, 2022 |
Exhibit 99.1 Gilead Contacts: Jacquie Ross, Investors [email protected] Meaghan Smith, Media [email protected] Jounce Contact: Eric Laub, Media and Investors [email protected], (857) 259-3853 GILEAD TO ACQUIRE ALL REMAINING RIGHTS TO POTENTIAL FIRST-IN-CLASS IMMUNOTHERAPY GS-1811 FROM JOUNCE THERAPEUTICS - Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 27, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. ASSET PURCHASE AND LICENSE AMENDMENT AGREEMENT This Asset Purchase and License Amendment Agreement (this “Agreement”), dated as |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2022 |
Exhibit 99.1 Jounce Therapeutics Reports Third Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, ca |
|
| August 30, 2022 |
Exhibit 99.2 Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients - SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor change over 9 |
|
| August 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 30, 2022 |
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY AUGUST 2022 Exhib i t 99. |
|
| August 4, 2022 |
Exhibit 99.1 Jounce Therapeutics Reports Second Quarter 2022 Financial Results - INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combination with pimivalimab; Data to be reported by year end - - Submitted two ab |
|
| August 4, 2022 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Jounce Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Jounce Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not emp |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERA |
|
| June 27, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2022 |
Exhibit 99.1 Jounce Therapeutics Reports First Quarter 2022 Financial Results - Two combination cohorts met initial response criteria for continued expansion in INNATE trial of JTX-8064; on track to present data on at least 60 Phase 2 patients across multiple cohorts in 2H2022 - - Target enrollment achieved in SELECT trial of vopratelimab in combination with pimivalimab; data expected in 2H2022 - |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THER |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Jounce Therapeutics Inc. (Name of Issuer) common stock (Title of Class of Securities) 481116101 (CUSIP Number) April 21, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ |
|
| March 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 7, 2022 |
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY MARCH 2022 Exhibit 99. |
|
| March 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 2, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Percentage Ownership Jounce Mass Securities, Inc. Massachusetts 100% |
|
| March 2, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Jounce Therapeutics, Inc. |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 2, 2022 As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. |
|
| March 2, 2022 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.6 Jounce Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Jounce Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not emp |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERAP |
|
| March 2, 2022 |
Exhibit 99.1 Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results - Continued execution on two proof-of-concept clinical trials for JTX-8064 and Vopratelimab, INNATE and SELECT, with clinical data on track for 2022 - - JTX-1484, a new antagonist antibody targeting LILRB4, enters IND-enabling activities representing the fifth internally discovered development program - - |
|
| February 14, 2022 |
JNCE / Jounce Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 14, 2022 |
JNCE / Jounce Therapeutics Inc / RTW INVESTMENTS, LP - JOUNCE THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G/A filed herewith (and any amendments thereto), relating to the common stock of Jounce Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of t |
|
| February 14, 2022 |
JNCE / Jounce Therapeutics Inc / Third Rock Ventures II, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2 )* Jounce Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
JNCE / Jounce Therapeutics Inc / PFM Health Sciences, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Jounce Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2021 Date of Event Which Requ |
|
| February 14, 2022 |
EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec |
|
| February 11, 2022 |
JNCE / Jounce Therapeutics Inc / ORBIMED ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Jounce Therapeutics, Inc. |
|
| February 11, 2022 |
CUSIP No. 481116101 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, $0.001 par value per share, of Jounce Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the |
|
| February 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule purs |
|
| January 10, 2022 |
Jounce Therapeutics Corporate Presentation A NEXT GEN IMMUNOTHERAPY COMPANY JANUARY 2022 Exhibit 99. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2021 |
Exhibit 99.1 Jounce Therapeutics Reports Third Quarter 2021 Financial Results - Commenced enrollment in tumor-specific monotherapy and pimivalimab combination expansion cohorts of INNATE trial of JTX-8064 - - Ended the quarter with $249.0 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., November 4, 2021 - Joun |
|
| November 4, 2021 |
PROSPECTUS SUPPLEMENT (To prospectus dated May 19, 2021) Jounce Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255760 PROSPECTUS SUPPLEMENT (To prospectus dated May 19, 2021) $75,000,000 Jounce Therapeutics, Inc. Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the te |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE |
|
| November 4, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 4, 2021 |
JOUNCE THERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT November 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Jounce Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of t |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 1, 2021 |
JNCE / Jounce Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 5, 2021 |
Exhibit 10.1 NON-QUALIFIED STOCK OPTION AGREEMENT INDUCEMENT GRANT FOR COMPANY EMPLOYEES FOR JOUNCE THERAPEUTICS, INC. Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Vesting Commencement Date: Grant Date: Expiration Date: Jounce Therapeutics, Inc. (the ?Company?) hereby grants to the Optionee named above an option (the ?Stock Option? or the ?Award?) to purchase on or pr |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 5, 2021 |
Exhibit 99.1 Jounce Therapeutics Reports Second Quarter 2021 Financial Results - INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021- - Announced two additional LILRB family targets as potential future development candidates - - Ended the quarter with $246.1 million in cash, cash equivalents and |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERA |
|
| June 23, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 17, 2021 |
JOUNCE THERAPEUTICS, INC. 780 Memorial Drive Cambridge, MA 02139 JOUNCE THERAPEUTICS, INC. 780 Memorial Drive Cambridge, MA 02139 May 17, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Jounce Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-255760 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as a |
|
| May 4, 2021 |
Exhibit 4.8 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| May 4, 2021 |
As filed with the Securities and Exchange Commission on May 4, 2021 Registration No. |
|
| May 4, 2021 |
Form of Subordinated Indenture Exhibit 4.7 JOUNCE THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314 |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THER |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 4, 2021 |
Exhibit 4.6 JOUNCE THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| May 4, 2021 |
Exhibit 99.1 Jounce Therapeutics Reports First Quarter 2021 Financial Results - Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the quarter with $271.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8: |
|
| May 4, 2021 |
Exhibit 4.9 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 481116101 (CUSIP Number) November 20, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| April 5, 2021 |
Exhibit 99.1 Joint Filing Agreement The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. The undersigned also agree that |
|
| March 10, 2021 |
Jounce Therapeutics Announces Proposed Offering of Common Stock Exhibit 99.1 Jounce Therapeutics Announces Proposed Offering of Common Stock CAMBRIDGE, Mass., Mar. 9, 2021 – Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The proceeds of |
|
| March 10, 2021 |
Exhibit 1.1 JOUNCE THERAPEUTICS, INC. 5,000,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement March 9, 2021 Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Cowen and Company, LLC 559 Lexington Avenue New York, New York 10022 c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 900 Minneapolis, MN 5540 |
|
| March 10, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 10, 2021 |
Prospectus supplement (to prospectus dated May 1, 2018) 5,000,000 shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223518 Prospectus supplement (to prospectus dated May 1, 2018) 5,000,000 shares Common Stock We are offering 5,000,000 shares of our common stock Our common stock is quoted on the Nasdaq Global Select Market under the symbol ?JNCE?. On March 9, 2021, the last reported sale price of our common stock on the Nasdaq Global Select |
|
| March 10, 2021 |
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock Exhibit 99.2 Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock CAMBRIDGE, Mass., Mar. 9, 2021 ? Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5,000,000 shares of common st |
|
| March 9, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223518 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is not an offer to sell these securities and we are not soliciting offers to buy these securities in any state or jurisdiction where the offer or sale is not permitted. Prospectus suppleme |
|
| February 25, 2021 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.5 Jounce Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Jounce Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not emp |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 25, 2021 |
List of Subsidiaries of the Registrant EX-21.1 3 jnce12312020exhibit211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Percentage Ownership Jounce Mass Securities, Inc. Massachusetts 100% |
|
| February 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERAP |
|
| February 25, 2021 |
As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. |
|
| February 25, 2021 |
Exhibit 99.1 Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results - Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CA |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 )* Jounce Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 481116101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Jounce Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) January 20, 2021 Date of Event Which Require |
|
| February 1, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Jounce Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the |
|
| January 29, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) January 19, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| January 11, 2021 |
jnce01112021exhibit991 Jounce Therapeutics A Next Gen Immunotherapy Company January 2021 Legal Disclaimer Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for our product candidates and any future product candidates, the |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 6, 2020 |
Exhibit 99.1 Jounce Therapeutics Reports Third Quarter 2020 Financial Results -On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT biomarker selection trial of vopratelimab in combination with JTX-4014- -Company to host conference call and webcast today at 8:00 AM ET- CAMBR |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE |
|
| November 6, 2020 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT by and between JOUNCE THERAPEUTICS, INC. and GILEAD SCIENCES, INC. dated as of August 31, 2020 Table of Conte |
|
| November 6, 2020 |
Exhibit 10.3 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 31, 2020, is by and bet |
|
| November 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 6, 2020 |
Exhibit 10.2 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of August 31, 2020 (the “Execution Date”), |
|
| November 2, 2020 |
Exhibit 99.1 Jounce Therapeutics Announces Update on Vopratelimab Program - No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in immunotherapy naïve biomarker-selected NSCLC- -Company to host conference call and webcast today at 8:00AM ET- CAMBRIDGE, Mass |
|
| November 2, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 26, 2020 |
JNCE / Jounce Therapeutics, Inc. / GILEAD SCIENCES INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Jounce Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 481116101 (CUSIP Number) October 16, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| September 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 1, 2020 |
Exhibit 99.1 Gilead Contacts: Jounce Contact: Douglas Maffei, PhD, Investors Komal Joshi, Investors and Media (650) 522-2739 (857) 320-2523 Marni Kottle, Media (650) 522-5388 For Immediate Release GILEAD SCIENCES AND JOUNCE THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR NOVEL IMMUNOTHERAPY PROGRAM – Gilead Will Have Exclusive Rights to Develop and Commercialize Anti-CCR8 Antibody – – Gilead |
|
| August 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERA |
|
| August 7, 2020 |
Exhibit 99.1 Jounce Therapeutics Reports Second Quarter 2020 Financial Results - Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in 2020 - - Ended the quarter with $127.2 million in cash, cash equivalents and investments - - Company to host conference call |
|
| August 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 30, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 4, 2020 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THER |
|
| May 6, 2020 |
Exhibit 99.1 Jounce Therapeutics Reports First Quarter 2020 Financial Results - Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 - - Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting - - Ended the quarter with $148.6 million in cash, cash equivalents and investments - - Company to host conference call and webcast tod |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin |
|
| April 7, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 7, 2020 |
jnce040720991 Exhibit 99.1 Jounce Therapeutics A Next Gen Immunotherapy Company April 2020 Legal Disclaimer Various statements concerning our future expectations, plans and prospects, including without limitation, our expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for our product candidates and any future product candidates, t |
|
| February 27, 2020 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Organization Percentage Ownership Jounce Mass Securities, Inc. Massachusetts 100% |
|
| February 27, 2020 |
JNCE / Jounce Therapeutics, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERAP |
|
| February 27, 2020 |
Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock, $0.001 par value per share (the “Common Stock”), of Jounce Therapeutics, Inc. (“us,” “our,” “we” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Ex |
|
| February 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 27, 2020 |
As filed with the Securities and Exchange Commission on February 27, 2020 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No. |
|
| February 27, 2020 |
Exhibit 99.1 Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results - On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRID |
|
| January 23, 2020 |
8-K 1 jnce012320208-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdict |
|
| January 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 13, 2020 |
jnce01132020exhibit991 Jounce Therapeutics A Next Gen Immunotherapy Company Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for Jounce’s product candidates and any future product candidates, t |
|
| December 17, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 17, 2019 |
PROSPECTUS SUPPLEMENT (To prospectus dated May 1, 2018) Jounce Therapeutics, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223518 PROSPECTUS SUPPLEMENT (To prospectus dated May 1, 2018) $50,000,000 Jounce Therapeutics, Inc. Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the ter |
|
| December 17, 2019 |
Exhibit 1.1 JOUNCE THERAPEUTICS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT December 17, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Jounce Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during |
|
| November 7, 2019 |
JNCE / Jounce Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE |
|
| November 7, 2019 |
Exhibit 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AGREEMENT by and among JOUNCE THERAPEUTICS, INC., CELGENE CORPORATION, and CELGENE RIVOT LLC dated as of July 22, 2019 |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 7, 2019 |
Exhibit 99.1 Jounce Therapeutics Reports Third Quarter 2019 Financial Results - New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash burn guidance reduced - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., November 7, 2019 - J |
|
| September 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 4, 2019 |
jnce090419exhibit991 Exhibit 99.1 Jounce Therapeutics A Next Gen Immunotherapy Company Legal Disclaimer Various statements concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding the timing, progress and results of discovery programs, preclinical studies and clinical trials for Jounce’s product candidates and any future product ca |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 7, 2019 |
Exhibit 99.1 Jounce Therapeutics Reports Second Quarter 2019 Financial Results - Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with Celgene, received $50.0 million upfront - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., August 7, |
|
| August 7, 2019 |
JNCE / Jounce Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-37998 JOUNCE THERA |
|
| July 23, 2019 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 13, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 JOUNCE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37998 45-4870634 (State or Other Jurisdiction of Incorporation) (Commission |
